Skeletal muscle loss, commonly known as sarcopenia, is highly prevalent and prognostic of adverse outcomes in oncology. However, there is limited information on adults with early breast cancer and examination of other skeletal muscle indices, despite the potential prognostic importance. This study characterizes and examines age-related changes in body composition of adults with early breast cancer and Skeletal muscle index and density provide independent, complementary information, and the product of the two metrics, skeletal muscle gauge, requires further research to explore its impact on outcomes in women with curable breast cancer.
| INTRODUCTION
With an estimated 246 000 new cases in 2016, breast cancer is the most common new cancer diagnosis in the United States and one of the leading causes of cancer mortality in women worldwide. 1 Nearly one-third of U.S. patients with breast cancer are over age 65 and in other developed countries this percentage may rise to 40%. 2 Increasing our awareness of considerations for treating the older breast cancer population will be important in caring for a large and growing population of adults with breast cancer.
Decreased skeletal muscle mass, commonly known as sarcopenia in oncology, is a common finding in adults with cancer and has been associated with increased treatment related toxicities and poorer survival in a myriad of cancer treatment settings. 3 However, less is known about the body composition of adults with early stage breast cancer. A recent study of patients with metastatic disease found a correlation between pre-existing sarcopenia and treatment toxicity. 4 Another study of breast cancer survivors found that sarcopenia was associated with overall mortality and may increase breast-cancer related mortality. 5 Routine computed tomography (CT) imaging can be utilized to assess muscle mass, but it is also able to assess muscle radiodensity and other nonmuscular body composition measures. Radiodensity is a qualitative measure of muscle composition, conveying the degree of myosteatosis or fatty infiltration of muscle tissue. 6 This metric, similar to skeletal muscle mass, can confer prognostic value for cancer outcomes. [7] [8] [9] [10] One study of metastatic breast cancer showed that low CT-derived muscle radiodensity associated with reduced overall survival and time to next treatment. 11 Adipose tissue content, including subcutaneous (SAT) and visceral adipose tissue (VAT), can also be determined from CT imaging, and has also been associated with treatment outcomes. For instance, CT-derived visceral adiposity has been linked to doxorubicin toxicity in a curable breast cancer population. 12 The goal of this study was to characterize the body composition of adults with early stage breast cancer (stage I-III) across a wide spectrum of age ranges and examine age-related changes in body composition. In addition, we describe the development of an integrated measure of skeletal muscle-Skeletal Muscle Gauge-that combines skeletal muscle mass and radiodensity into a novel composite measure.
2 | ME TH ODS 
| CT-based body composition analysis
Skeletal muscle area was measured using established methodology. 13 In brief, abdominal CT images were acquired from the UNC 
| Statistics
Differences between age groups were analyzed using Pearson's chisquare tests for categorical variables, and ANOVA, with a two-sided post-hoc analysis (Tukey's multiple comparisons test), for continuous variables. Correlations were assessed using Pearson correlation coefficients (rho). Linear regression was used to quantify the relationship between continuous variables by estimating the slope of the best-fit line. In all instances, the phrase "significantly different" denotes P < .05. Analyses were conducting using GraphPad Prism and SAS statistical software (Cary, NC, USA).
| RESULTS
Using the NC tumor registry, 1217 nonrepeating entries and 1080 records were accessible in the electronic medical record. 480 of these patients had received abdominal CT imaging for staging purposes of which 241 patients had received the abdominal CT scan within 12 weeks of breast cancer diagnosis. 3.2 | Body composition measures Table 1 also presents age-stratified body composition metrics. Overall, many skeletal muscle measures were significantly lower in the 65+ age bracket vs the <50 age group, including skeletal muscle area, SMI, SMD, and SMG (P < .001). The 65+ group was significantly different from the aged 50-64 group for SMI and SMD as well (P < .001, P < .01 respectively). SMG showed sharply decreasing values between the <50, 50-64, and 65+ groups. VAT showed an opposite pattern as the skeletal muscle metrics, with mean values increasing across aged groups (65+ vs <50, P < .01, 50-64 vs <50,
The overall proportion of sarcopenic patients in our study was 34%. A significantly greater number of older patients (≥65) were sarcopenic (63%) than patients in the other age groups (28% for <50, P < .001 and 32% for 50-64, P < .01). Significantly more 50-64 and 65+ years old patients were considered myosteatic than patients <50 years old (P < .001). Very few (8%) of patients aged <50 were both sarcopenic and myosteatic, whereas 26% of patients aged 50-64 and 57% of patients aged 65 + (65+ vs both other age groups, P < .001) met this criteria. We examined the proportion of combined sarcopenic and obese patients per group as well, and found no patients meeting these criteria in the <50 age group, but 8% and 10% of the 50-64 and 65+ age groups met criteria respectively. 
| Skeletal muscle index (SMI) and skeletal muscle density (SMD) correlations
Overall, SMI decreased as age increased, but had a very weak correlation (q = 0.20, Figure 1A ). For every one-year increase in age, SMI decreased approximately 0.13 units. SMI was strongly positively correlated with BMI (slope = 0.68 q = 0.60, Figure 1C ). SMI increased slightly as visceral fat increased (slope = 0.03, Figure 1E ) and was more strongly correlated with BMI (q = 0.59, Figure 1C ) than age (q = 0.20, Figure 1A ). SMD decreased as age increased (q = 0.46, Figure 1B ). For every 1-year increase in age, SMD decreased by 0.36 units. SMD decreased dramatically as BMI increased (slope = À0.72, q = 0.52, Figure 1D ), and decreased as VAT increased (slope = À0.08, q = 0.68, Figure 1F ). Variability in SMD was more strongly correlated with VAT (q = 0.68, Figure 1F ), than BMI (q = 0.52) or age (q = 0.46). A comparison of SMI to SMD found a very minimal negative correlation between the two indices (q = 0.14) (Figure 2 ).
F I G U R E 1 Scatter plots of SMI and SMD. (A) Skeletal Muscle Index (SMI) vs Age of Diagnosis. (B) Skeletal Muscle Density (SMD) vs Age of Diagnosis. (C) SMI vs Body Mass Index (BMI). (D) SMD vs BMI. (E) SMI vs Visceral Adipose Tissue (VAT). (F) SMD vs VAT. rho and slopes (m)
for the correlations are indicated on the individual graphs. VAT values were drawn on a log 2 scale based on the wide ranging data stratification, and the best fit line represents a straight line fit 
| CONCLUSIONS
In this study, we examined the body composition of women diagnosed with early stage breast cancer using abdominal CT images obtained as part of routine oncologic care and examined age-related differences in body mass composition. We found wide variation in body composition variables across the age spectrum and a high prevalence of sarcopenia and myosteatosis that was most prevalent in the ≥65 population. This is consistent with other studies of sarcopenia in adults with cancer, 16 and the overall proportion of sarcopenic patients in our population was somewhat higher than that expected in a healthy population of women. 17 While sarcopenia, defined by SMI alone, has offered substantial prognostic value in a number of studies, 18 it is by no means the only valuable CT-based body composition metric available to researchers.
SMD conveys the composition of muscle tissue, independent of muscle quantity, and is inversely related to fatty infiltration of skeletal muscle, known as myosteatosis. SMD is prognostic of survival in gastrointestinal, 7, 8 pancreatic, 9 and lung cancers, 8 with independent prognostic value from SMI. 8 Indeed, at least two studies have found prognostic relationship of SMD but not SMI on overall survival. 10, 19 One study, of unresectable pancreatic cancer patients, found that higher myosteatosis but not sarcopenia was correlated with increased systemic inflammation and reduced survival. 10 Another study of patients with metastatic renal cell carcinoma, found that SMD but not SMI has positive prognostic relationship with overall survival and progression-free survival. 19 These findings strongly support the independent value of myosteatosis from sarcopenia. In comparing SMI to SMD in our study, several salient similarities and differences can be drawn. Given the implicit significance of age to the definition of sarcopenia, the fact that SMG has a stronger correlation with age in a curable breast cancer population is exciting, and warrants further study. Our study has some limitations. First, it was limited by the number of patients older than 65 in our dataset. However, given the large age-related group differences we observed and more importantly the focus on age as a continuous rather than grouped value, we expect that these results will replicate in larger older patient populations. One challenge to studying patients with curable breast cancer is the overall lack of CT imaging available as staging CT scans are recommended only for patients with Stage III breast cancer. 24 Here, only 22% of all patients in the patient registry data base received abdominal CTs within our predetermined cut-off of 12 weeks surrounding the date of diagnosis, and therefore our findings may not be representative of all patients with early breast cancer. Also, the declared cutoff ranges for sarcopenic and myosteatic patients, though based on previous literature, may not prove appropriate for the nonmetastatic breast cancer population, nor be predictive of outcomes for these patients. Finally, it is challenging to compare body composition values to outcomes in this population of patients with curable breast cancer as the absolute recurrence and mortality rate in this population to date remains extremely low.
However, it will be valuable to continue following these individuals over time to assess these long-term measures.
In conclusion, this is the largest study to date systemically characterizing CT-based body composition measures in adults with potentially curable breast cancer. We present a new metric, skeletal muscle gauge, which correlates better with aging than either SMD or SMI and has already shown great value in predicting oncological outcomes. Due to the ease of generating these body composition measures from routine CT imaging, we foresee oncologists incorporating skeletal muscle metrics to improve prognostication and identify patients at-risk for adverse outcomes. These patients could benefit from supportive interventions, such as resistance exercise therapy, which has been shown to reverse sarcopenia and associated with improved quality of life. 
